Recently, Ching-Sheng Hsu et al. demonstrated a clinically effective role of IL-21R genotype in predicting IFN-based therapeutic response in Asian chronic hepatitis C patients with unfavorable IL28B genotype. This evidence concerns the gene IFNL3 and chronic hepatitis C virus infection.